Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770566 | 0.89 | PI4KB (0.35) | PI4KBPI4KAMAPTTP53POLB | |
| SCHEMBL12598918 | 0.88 | HCAR3 (0.38) | HCAR3MAPTTP53LMNAPOLB | |
| SCHEMBL691139 | 0.87 | MAPT (0.33) | HCAR3PI4KBPI4KAMAPTTP53 | |
| SCHEMBL1770533 | 0.85 | HCAR3 (0.38) | HCAR3MAPTTP53LMNAPOLB | |
| SCHEMBL1770530 | 0.84 | HCAR3 (0.41) | HCAR3PI4KBMAPTTP53LMNA | |
| SCHEMBL1770509 | 0.84 | HCAR3 (0.36) | HCAR3MAPTTP53LMNAPOLB | |
| SCHEMBL12598916 | 0.84 | HCAR3 (0.38) | HCAR3PI4KBMAPTTP53LMNA | |
| SCHEMBL693037 | 0.82 | HCAR3 (0.39) | HCAR3MAPTTP53LMNAPOLB | |
| SCHEMBL1770680 | 0.81 | HCAR3 (0.35) | HCAR3MAPTTP53LMNAPOLB | |
| SCHEMBL1118503 | 0.81 | PI4KB (0.36) | HCAR3PI4KBPI4KAFPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421871-B1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2421871-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| WO-2010122071-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122071-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | CCNA1, MKI67, CCNT1 | HCAR3 3378/4885PI4KB 4844/4885PI4KA 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.